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Prostate cancer is the second-leading cause of cancer-related deaths in men in the United States. Unfortunately,
there is no effective therapy when prostate cancer becomes metastatic and refractory to conventional treatments. For
this reason, the identification and exploration of new agents that reduce prostate cancer cell growth are of paramount
importance. High consumption of plant-derived phytoestrogens is inversely associated with the incidence and
mortality rate of prostate cancer. Previous studies, including our own, have shown that the phytoestrogen genistein
inhibits prostate cancer cell growth in vitro and in vivo and decreases secreted and intracellular levels of the androgen-
regulated protein prostate-specific antigen (PSA), but the role of genistein as an agonist/antagonist for hormone
receptors remains unclear. To elucidate the mechanism by which genistein modulates PSA protein expression in
prostate cancer cells, we investigated the effects of genistein on androgen-mediated and estrogen-mediated
transcriptional regulation of PSA, androgen receptor (AR) mRNA and protein expression, and the ability of nuclear
proteins to bind to androgen-response elements (AREs) in LNCaP cells. We showed that genistein decreased the
transcriptional activation of PSA by both androgen-dependent and androgen-independent methods in LNCaP cells.
The reduction of androgen-mediated transcriptional activation of PSA was correlated with decreased AR protein and
mRNA levels and decreased binding to AREs. In contrast, genistein had differential effects on 17b-estradiol–mediated
PSA expressions. Low concentrations of genistein enhanced 17b-estradiol–mediated PSA expressions, whereas high
concentrations of genistein inhibited estrogen-mediated PSA expression in LNCaP cells. Genistein did not inhibit AR
protein expression in the presence of 17b-estradiol. These results suggest that ligand-dependent differences in the
ability to activate PSA expression may contribute to the agonistic/antagonistic responses observed with genistein in
prostate cancer cells.  2002 Wiley-Liss, Inc.
Key words: prostate-specific antigen; androgen receptor; gene regulation; genistein
INTRODUCTION
Prostate cancer is the most common malignancy
and the second-leading cause of cancer-related
deaths in men in the United States [1]. Androgens
and the androgen receptor (AR) play an important
role in the development and maintenance of the
prostate gland and are involved in prostate tumor-
igenesis [2]. The AR is a ligand-specific nuclear
transcription factor that binds with high affinity to
androgens. The AR transactivates the expression of
genes, including prostate-specific antigen (PSA),
by binding to androgen-response elements (AREs)
located in the promoter [3]. Most prostate cancers
are initially androgen dependent, and therefore
androgen-ablation therapy leads to tumor regres-
sion [4]. Currently, treatments for prostate cancer
are based on surgical or chemical castration, which
results in decreased circulating androgens and
reduces prostate size [5]. Unfortunately, prostate
cancer eventually becomes refractory to androgen
deprivation and recurs despite continued therapy.
It has been postulated that several molecular
mechanisms are responsible for the development of
hormone-refractory prostate cancer. A majority of
these mechanisms involve alterations in the func-
tion of the AR and its signaling pathways. Studies on
prostate tissues from human patients have shown
that nearly all cancer tissue retains AR expression
regardless of clinical stage or hormone responsive-
ness. One-third of androgen-independent tumors
show amplification and overexpression of the AR
gene, suggesting that a functional ARpathway favors
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cell growth [6]. The most frequent AR mutation
found in prostate cancer patients is the replacement
of threonine 877with alanine, which corresponds to
the mutation seen in the LNCaP prostate cancer cell
line [7–9]. This mutation alters the ligand specificity
of the receptor such that estrogens, progesterone,
adrenal steroids, and anti-androgens can activate the
mutant AR, thereby promoting cell growth [10].
Increased expression of AR has been noted in
recurrent hormone-independent tumors [11] and
may play a role in the failure of conventional
androgen-deprivation therapy in advanced prostate
cancer [12]. Therefore, identifying agents that mini-
mize or eliminate AR transactivationmay be a useful
strategy to prevent and treat prostate cancer.
There is strong epidemiological evidence to sug-
gest that soy isoflavones have a preventative effect
against the development of prostate cancer. Chinese
and Japanese men, who consume large quantities of
isoflavones, have significantly lower prostate cancer
incidence and mortality rates [13,14]. Genistein, a
major soy isoflavone, has been shown to inhibit the
cell growth of several types of cancer, including
prostate [15,16], breast [17,18], lung [19], and head
and neck [20] cancer and leukemia and lymphomas
[21]. There are several known biological effects of
genistein that may contribute to its antiproliferative
effect against cancer. Genistein is a known tyrosine
kinase inhibitor [22]; it also inhibits topoisomerase
[23] and angiogenesis [24] and induces differentia-
tion in breast cancer cells [25] and apoptosis in
prostate cancer cell lines [16]. The exact molecular
mechanism by which genistein inhibits tumor cell
growth has not been clearly identified, however.
Previous studies, including our own, have shown
that the soy isoflavone genistein inhibits prostate
cancer cell growth in vitro and in vivo while re-
ducing PSA levels [26,27]. PSA, an androgen-respon-
sive gene, produces a protein, which is a known
biological tumor marker used to detect and monitor
the treatment of prostate cancer patients [28,29].
The mechanism by which genistein inhibits PSA
protein expression is unknown; for this reason, we
investigated the effects of genistein on AR mRNA
and protein expression and its functional ability to
bind to AREs and ultimately promote androgen-
mediated PSA gene transactivation. We found that
genistein treatment decreased AR at the mRNA
and protein levels, decreased binding of nuclear
proteins to AREs, and inhibited PSA gene transacti-
vation in an androgen-dependent and androgen-
independent manner. Additionally, we showed
that genistein differentially modulated estrogen-
mediated PSA expression in a dose-dependent
manner. Low concentrations of genistein actually
enhanced 17b-estradiol–mediated PSA expression,
whereas high concentrations inhibited PSA expres-
sion. These results showed the pleiotropic effects
of genistein on hormone signaling pathways in
prostate cancer cells, suggesting the complexity of
AR/PSA regulation in vivo by genistein.
MATERIALS AND METHODS
Cell Culture
The human prostate cancer cell line LNCaP was
purchased from the American Type Culture Collec-
tion (Rockville, MD). LNCaP cells were maintained
in RPMI 1640 (GIBCO, Gaithersburg, MD) and sup-
plemented with 5% fetal calf serum, unless other-
wise indicated, with 1% penicillin/streptomycin at
378C and 5% CO2.
Cell Treatment
LNCaP cells were grown to 60–70% confluence,
washed twice with serum-free RPMI 1640 medium,
and incubated in medium containing 10% dextran-
coated charcoal (DCC)–stripped serum in the pre-
sence or absence of 1010 mM R1881 (NEN, Boston,
MA) or 1 mM b-estradiol (Sigma, St. Louis, MO).
Twenty-four hours later, the cells were treated with
either genistein (Toronto Biolabs, Toronto, Canada)
or daidzein (BioMol, Plymouth Meeting, PA) at the
indicated concentrations for an additional 24 h.
Probe Preparation for Northern Blot Analysis
A 22-bp oligonucleotide, upper sequence (50-TC-
CAGAGCGTGCGCGAAGTGAT-30) and lower sequ-
ence (50-AGCTATCCATCCAGGGGCCCAT-30), was
used for the amplification of an AR cDNA fragment
from the total RNA extracted from LNCaP cells fol-
lowing standard methodology. Briefly, 1 mg of total
RNA was subjected to single-strand cDNA synthesis
with the THERMOSCRIPT RT-PCR System (Invitro-
gen, Carlsbad, CA) and amplified by polymerase
chain reaction. Following polymerase chain reac-
tion amplification, the amplicons were separated
through an 0.8% agarose gel and stained with ethi-
dium bromide; the DNA was excised from the gel,
purified, and labeled with [a-32P]ATP (DuPont NEN,
Boston, MA) with the Random Primer Labeling Kit
(Stratagene, Cedar Creek, TX). The probe was puri-
fied with Stratagene purification columns and used
for Northern hybridization.
Northern Blot Analysis
LNCaP cells were plated on 100-mm dishes and
treated with 0, 0.5, 5, and 50 mMgenistein for 12 and
24 h. Total RNA was extracted from each sample
with the TRIzol method (Invitrogen, Carlsbad, CA),
followed by phenol-chloroform extraction and iso-
propanol precipitation. Northern gel electrophor-
esis was performed with 20 mg of total RNA per lane
in a denaturing gel in 1 MOPS buffer (20 mM
MOPS, 1 mM EDTA, and 1 mM NaOAC at pH 7.0),
followed by overnight blot transfer in 10 standard
saline citrate (1.5 M NaCl and 0.15 M Na citrate
at pH 7.0) to a nylon membrane (Hybond Nþ;
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Amersham Life Sciences, Piscataway, NJ). Hybridiza-
tion was performed overnight at 658C in 0.25 M
Na2HPO4 and 7% sodium dodecyl sulfate contain-
ing 2106 cpm/mL a-32P–labeled AR and a b-actin
probe. The membrane was washed sequentially in
20 mM Na2HPO4 and 5% sodium dodecyl sulfate,
followed by 20 mM Na2HPO4 and 1% sodium
dodecyl sulfate.
Autoradiographs were obtained by exposing the
membrane for 20 h at 708C. The signal was
quantitated for AR mRNA as well as for b-actin
mRNA by scanning the signals with a Gel Doc 1000
image scanner (Bio-Rad, Hercules, CA). The bidi-
mensional optical densities of AR and b-actin mRNA
expression on the films were quantified and ana-
lyzed with Molecular Analyst software (Bio-Rad).
The ratios of AR mRNA expression against b-actin
were calculated and plotted with GraphPad Prism
software (GraphPad Software Inc., San Diego, CA).
Transient Transfection
LNCaP cells were plated in 35-mm dishes until
they reached 60–70% confluence. Cells were co-
transfected with a cytomegalovirus–b-galactosidase
expression vector and pGL3 containing a 6-kb PSA
promoter construct in front of a luciferase reporter
gene (gift from Dr. Charles Young, Mayo Clinic,
Rochester,MN)with Tfx50 (Promega,Madison,WI),
following the manufacturer’s protocol. Twenty-four
hours after transfection, cells were washed with
serum-free RPMI medium and reincubated for an
additional 24 h inmedium containing either 0.1 nM
R1881 or 1 mM b-estradiol with the indicated con-
centrations of genistein. Whole-cell extracts were
prepared, and the luciferase assay was performed
according to the manufacturer’s protocol (Promega).
The activity of b-galactosidase was assayed with the
manufacturer’s protocol (Tropix, Bedford, MA) for
normalization of transfection efficiency. Each trans-
fection was performed three times, and standard
deviations were calculated and data analyzed with
GraphPad Prism statistical software (GraphPad Soft-
ware Inc.).
Western Blot Analysis
LNCaP cells were plated in 35-mm dishes and
grown to 60–80% confluence. The cells were
washed twice with serum-free RPMI 1640 media
and reincubated with media containing 0.1 nM
R1881 or 1 mM b-estradiol. Twenty-four hours later,
the cells were treated with the indicated concentra-
tions of genistein or daidzein for an additional 24 h.
Whole-cell extracts were harvested, and protein
concentrations were determined by BCA protein
assay (Bio-Rad). Protein samples were loaded onto
either a 6% or a 12% acrylamide gel and subjected to
gel electrophoresis. Protein samples were transferred
to a nitrocellulose membrane. The membranes were
blocked for 1 h in 10% nonfat dry milk in TBST
(20 mM Tris-HCl at pH 7.6, 137 mMNaCl, and 0.1%
Tween 20). The membranes were incubated over-
night at 48C in 5% milk/TBST containing primary
antibodies to AR (Neomarkers), PSA (Pharmingen,
San Diego, CA), or b-actin (Bio-Rad). The mem-
branes were washed three times for 10 min each in
TBST and then incubated with anti-mouse horse-
radish peroxidase secondary antibody (Bio-Rad) for
1 h at room temperature. The membranes were
washed three times for 10 min each in TBST, and
the signal was detected with the chemilumines-
cence detection system (Pierce, Rockford, IL). Auto-
radiograms of Western blots were scanned with the
Gel Doc 1000 image scanner (Bio-Rad), and the
optical density was determined with Molecular
Analyst software (Bio-Rad).
Preparation of Nuclear Proteins
LNCaP cells were plated at a density of 1106 in
100-mm dishes and cultured for 24 h. Subsequently,
the cultures were treated with or without genistein
for an additional 24 h. Cells were harvested by a cell
scraper and washed with phosphate-buffered saline.
The cell pellet was resuspended in 0.5 mL of 10 mM
Tris-HCL (pH 7.5), 5 mM MgCl2, and 0.05% (vol/
vol) Triton X-100 and lysed with 20 strokes with a
1-mL Dounce homogenizer. The homogenate was
centrifuged at 1000 g for 10 min at 48C. The super-
natant (cytosolic extract) was collected and frozen
at 708C until further use. The nuclear pellet was
treated further for nuclear protein extraction. The
pellet volume was estimated and resuspended in an
equal volume of 10 mM Tris-HCl and 5 mM MgCl2,
followed by the addition of one nucleus pellet
volume of 1 M NaCl, 10 mM Tris-HCL (pH 7.5), and
5 mM MgCl2. The lysing nucleus was left on ice for
30min and then centrifuged at 10000g for 15min.
at 48C. The supernatant was removed, and 80%
glycerol was added to a final glycerol concentration
of 20% (vol/vol). A BCA protein assay was con-
ducted to determine the protein concentration of
each sample.
Labeling of ARE Oligo with [g-32P]ATP
The following reagents were assembled for the
phosphorylation reaction: 3 pmol of the consensus
double-stranded oligonucleotide 50-AGTTGAGGG-
GACTTTCCCAGG-30 (ARE) DNA binding sequence
obtained from Santa Cruz Biotechnology (Santa
Cruz, CA), 5T4 polynucleotide kinase buffer, 1 U
of T4 polynucleotide kinase, nuclease-free water,
and 10 mCi of [g-32P]ATP in a total volume of 10 mL.
The reaction was incubated for 10 min at 378C, and
the reaction was stopped with the addition of 0.5 M
EDTA. The [g-32P]ATP-labeled ARE consensus se-
quence was purified with Stratagene Nucprobe
(Stratagene, La Jolla, CA). A gel shift assay was per-
formed as previously described [30].
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RESULTS
Genistein Decreased AR Protein Expression
in LNCaP Cells
We previously found that genistein inhibits
PSA secretion, protein expression, and mRNA levels
in LNCaP cells [26]. PSA is an androgen-responsive
gene and is mainly regulated by the AR; for this
reason, we examined whether genistein modulates
protein expression of the AR, which, in turn, may
modulate PSA expression. LNCaP cells were cultured
in the absence and presence of 0.1 nM R1881, a
nonmetabolized synthetic androgen, and treated
with increasing concentrations of genistein. In the
absence of androgen, genistein decreased AR pro-
tein levels in a dose-dependent manner (Figure 1A).
A 25% reduction in AR protein expression was
observed in LNCaP cells treated with 5 mM geni-
stein for 24 h. Cells treated with 30 and 50 mM
genistein had 70% and 96% reductions in AR pro-
tein expression, respectively. The inhibitory effect
of genistein on AR protein expression was enhanc-
ed in the presence of R1881 (Figure 1B). LNCaP
cells treated with 0.5 mM genistein had a 45%
decrease in AR protein levels, those treated with
1 mM genistein had a 80% reduction, and those
treated with 10 mM genistein had a 92% reduction;
AR was barely detectable with 50 mM genistein.
These results showed that genistein reduced AR
protein expression in LNCaP cells and that the inhi-
bitory effect of genistein was greater in the presence
of androgen.
To determine whether the inhibitory effects of
genistein on AR expression were specific, we tested
whether daidzein, a compound that is structurally
similar to genistein, could inhibit AR and PSA
protein expression in LNCaP cells. Western blot
analysis showed that daidzein did not reduce PSA or
AR protein levels in LNCaP cells (Figure 2), indicat-
ing the specificity of genistein in the downregula-
tion of AR and PSA proteins.
Genistein Inhibited AR mRNA Expression
in LNCaP Cells
To investigate further the modulation of AR by
genistein, we conducted Northern blot analysis to
detect whether genistein had any effect on AR
mRNA levels. LNCaP cells were treated with 0, 0.5,
5, and 50 mM genistein for 12 h and 24 h, and the
total RNA was subjected to Northern blot analysis.
We observed a slight reduction ofARmRNA levels in
LNCaP cells treated with 0.5 and 5 mM genistein
within 12 h of treatment, but there was no similar
reduction in the 24-h treatment group when cor-
rected for gel loading, as measured by the expression
of b-actin mRNA. Nevertheless, a 75–80% reduction
in ARmRNA levels was noted in LNCaP cells treated
with 50 mM genistein for 12 h and 24 h (Figure 3),
indicating that high concentrations of genistein
inhibited ARmRNA levels. Further in-depth studies,
however, are needed to determine whether the
stability of the ARmRNA or other factors contribute
to the downregulation of AR mRNA in genistein-
treated prostate cancer cells.
Figure 1. Genistein inhibited AR protein expression levels in
LNCaP cells. LNCaP cells were cultured in medium containing DCC-
stripped serum (A) or supplemented with 0.1 nM R1881 (B) for 24 h
and subsequently were treated with 0, 0.5, 1, 5, 10, 30, and 50 mM
genistein for an additional 24 h. Whole-cell lysates were harvested,
and cell extracts were subjected to Western blot analysis for
the detection of AR protein with b-actin as a loading control.
Densitometric analysis was performed for each sample, and the data
were plotted as the optical density (O.D.) ratio of AR divided by
b-actin.
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Genistein Inhibited Androgen-Mediated and
Androgen-Independent PSA Promoter Activity
To assess whether genistein directly affected tran-
scriptional activity of PSA, we transiently transfect-
ed LNCaP cells with a 6-kb PSA promoter fragment
that contained three AREs in front of a luciferase re-
porter gene (pPSA-luc). An approximately 160-fold
induction of PSApromoter activitywas noted in cells
incubated in the presence of R1881 (Figure 4A).
Androgen-mediated PSA promoter activity was re-
pressed in genistein-treated cells in a dose-depen-
dent manner. Cells treated with 10 mM genistein
had a 25% reduction in PSA promoter activity
(P<0.001), those treated with 30 mM genistein
had a 72% reduction in PSA promoter activity
(P< 0.001), and those treated with 50 mM genistein
had a 93% reduction in PSA promoter activity
(P< 0.001) compared with control. To ensure that
genistein-mediated inhibition did not reflect toxic
or other nonspecific effects of the plasmid or differ-
ences in transfection efficiency, luciferase expres-
sion in all experiments was normalized with b-
galactosidase production in cells cotransfected with
b-galactosidase control plasmid. The decrease in PSA
promoter activity by genistein correlated with the
reduction of PSAmRNA levels found in our previous
study [26]. These results showed that genistein
inhibited androgen-mediated PSA promoter activity
in LNCaP cells in a dose-dependent manner.
We have previously shown that high concentra-
tions of genistein inhibits PSA protein expression
independent of androgen in VeCaP cells, a prostate
cancer cell line derived from a patient with a
hormone-refractory tumor that expresses PSA in an
androgen-independent manner [26]. Furthermore,
it has been shown that PSA can be transcriptionally
regulated in an androgen-independent manner
[31–33]. Therefore, we investigated whether genis-
tein inhibited PSA promoter activity in the absence
of androgen in LNCaP cells. Minimal PSA promoter
activity was observed in LNCaP cells maintained in
medium containing 10% DCC-stripped serum com-
pared with cells treated with R1881 (Figure 4B). Low
concentrations of genistein (1–10 mM) did not have
a significant inhibitory effect on promoter activity,
but 30 mM genistein decreased the activity by 60%
Figure 2. Daidzein did not inhibit PSA or AR protein expression
levels. LNCaP cells were treated with 0, 5, 10, 30, and 50 mM
daidzein for 24 h. Whole-cell lysates were harvested and subjected to
Western blot analysis for the detection of PSA and AR protein, and
b-actin was used as a loading control. O.D., optical density.
Figure 3. Genistein decreased AR mRNA levels. LNCaP cells were
treated with 0, 0.5, 5, and 50 mM genistein for 12 and 24 h. Total
RNA was subjected to Northern blot analysis to detect AR mRNA.
Detection of b-actin mRNA was used as a loading control. Densio-
metric analysis was performed for each sample, and the data were
plotted as the optical density (O.D.) ratio of AR divided by b-actin.
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Figure 4. Genistein inhibited androgen-induced PSA promoter
activity. (A) LNCaP cells were transfected with a 6-kb PSA promoter
fragment containing three AREs in front of a luciferase reporter gene
(pPSA-luc). Cells were treated in the presence or absence of 0.1 nM
R1881 and subsequently treated with 0, 5, 10, 30, and 50 mM
genistein for 24 h. Cell lysates were assayed for luciferase and
b-galactosidase (b-gal). Results are expressed as luciferase relative
light units/b-galactosidase. (B) LNCaP cells were transfected with
pPSA-luc in the absence of androgen and treated with 0, 5, 10, 30,
and 50 mM genistein for 24 h and assayed for luciferase and
b-galactosidase. Results are expressed as luciferase relative light
units/b-galactosidase.
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(P<0.001) and 50 mM genistein by 88% (P< 0.0001)
in the absence of exogenous androgen. These re-
sults suggested that both androgen-dependent and
androgen-independent mechanisms might have
been involved in the modulation of PSA signaling
pathways by genistein.
Correlation of PSA Expression with the Binding of
Nuclear Extracts to the ARE
Transcriptional regulation of PSA by androgens
occurs via the ARE in the promoter region of the PSA
gene. We examined whether a correlation existed
between the binding of nuclear proteins to the ARE
in the presence of genistein. LNCaP cells main-
tained in medium containing R1881 were treated
with increasing concentrations of genistein. Nuclear
protein extracts were harvested, incubated with a
radiolabeled ARE consensus sequence, and subjec-
ted to electrophoretic mobility shift assay. Figure 5
shows that the levels of nuclear protein binding to
the ARE decreased with increasing concentrations of
genistein. Nuclear extracts incubated with excess
unlabeled ARE consensus sequence competitively
inhibited binding to 32P-labeled ARE. Nuclear
protein binding to ARE was not detectable in the
absence of androgen (data not shown). These results
showed that the inhibition of androgen-mediated
PSA expression by genistein was due to decreased
binding of nuclear proteins to the ARE, which
probably resulted in the reduction of AR protein
expression.
Genistein Differentially Modulated Estrogen-Mediated
PSA Protein Expression in a Dose-Dependent Manner
It has been reported that estrogens bind to and
activate AR and regulate PSA expression in LNCaP
cells [34]. Genistein is structurally similar to 17b-
estradiol and has been reported to have estrogen-
like activities by acting as a growth stimulant to
estrogen-dependent breast cancer cells [35,36]. We
observed an increase in PSA protein expression
when we treated LNCaP cells with 1 mM 17b-estra-
diol (Figure 6). Lower concentrations of b-estradiol
did not significantly affect PSA protein levels. For
this reason, we assessed whether genistein modu-
lated PSA expression in the presence of 1 mM 17b-
estradiol in LNCaP cells. When we treated LNCaP
cells with genistein in the presence of b-estradiol, we
noted a biphasic response. Low concentrations of
genistein (0.5–5 mM) enhanced b-estradiol–induced
PSA, but treatment with 10 mM or 30 mM genistein
brought PSA levels back to baseline, and 50 mM
genistein inhibited PSA protein levels by 30%.
To determine whether the effect of genistein on b-
estradiol–mediated PSA expression occurred at the
transcriptional level, we transiently transfected
LNCaP cells with the plasmid construct pPSA-luc
in the presence and absence of 1 mM b-estradiol. As
seen in R1881-treated cells, b-estradiol–enhanced
PSA promoter activity approximately 100-fold com-
pared with cells maintained in medium containing
DCC-stripped serum (Figure 7). Treatment with low
concentrations of genistein (5–10 mM) slightly
enhanced PSA promoter activity, whereas higher
concentrations of genistein inhibited activity. These
results correlated with the protein levels shown
in Figure 6 and demonstrated that the genistein-
induced differential effect on b-estradiol–mediated
PSA expression was dose dependent. To understand
the mechanism by which genistein modulated b-
estradiol–mediated PSA expression, we conducted
Western blot analysis on protein extracts harvested
Figure 5. Genistein decreased nuclear protein binding to the ARE
in the presence of androgen. LNCaP cells were treated with 0.1 nM
R1881 for 24 h and subsequently treated with 0, 0.1, 0.5, 1, 5, 10,
and 50 mM genistein for an additional 24 h. Nuclear protein extracts
were harvested and incubated with a [g-32P]ATP-labeled ARE
consensus oligonucleotide. Samples were subjected to an enzyme-
linked immunosorbant assay to detect nuclear protein binding.
Competitive inhibition (CI) represents nuclear extracts of untreat-
ed LNCaP cells incubated with excess unlabeled ARE consensus
oligonucleotide.
Figure 6. Genistein differentially modulated b-estradiol–mediat-
ed PSA protein expression. LNCaP cells were treated with 1 mM
b-estradiol for 24 h and subsequently treated with 0, 0.5, 1, 5, 10,
30, and 50 mM genistein for an additional 24 h. Whole-cell lysates
were harvested and subjected to Western blot analysis for the
detection of PSA protein. O.D., optical density.
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from LNCaP cells maintained in 1 mM b-estradiol
and treated with increasing concentrations of geni-
stein. Figure 8 shows that genistein did not modu-
late AR protein levels in the presence of b-estradiol.
These results indicated that genistein had multiple
and pleiotropic effects on AR and PSA signaling
pathways, which may be regulated by the type of
ligand present and the functional status of the AR
in vivo.
DISCUSSION
In this report, we describe the inhibition of
androgen-dependent and androgen-independent
PSA via transcriptional mechanism by the soy iso-
flavone genistein. This effect was accompanied by
decreased AR protein and AR mRNA levels and
inhibition of nuclear protein binding to AREs in
LNCaP cells. The inhibitory effect of genistein on
PSA and AR protein levels was not observed with a
structurally similar soy isoflavone, daidzein. Addi-
tionally, we have shown that genistein modulated
b-estradiol–induced PSA expression in LNCaP cells
in a biphasic manner. Low concentrations of geni-
stein enhanced b-estradiol–induced PSA protein
expression and PSA promoter activity, whereas high
concentrations of genistein inhibited b-estradiol–
mediated PSA promoter activity and PSA expression.
These effects could not be explained by changes in
AR protein levels, demonstrating the diverse and
Figure 7. Genistein differentially modulated b-estradiol–mediated
PSA promoter activity. LNCaP cells were transfected with a 6-kb PSA
promoter fragment containing three AREs in front of a luciferase
reporter gene (pPSA-luc). Cells were treated in the presence or
absence of 1 mM b-estradiol and subsequently treated with 0, 5, 10,
30, and 50 mM genistein for 24 h. Cell lysates were assayed for
luciferase and b-galactosidase. Results are expressed as luciferase
relative light units/b-galactosidase.
Figure 8. Genistein did not modulate AR protein expression levels
in the presence of b-estradiol. LNCaP cells were treated with 1 mM
b-estradiol for 24 h and subsequently treated with 0, 0.5, 1, 5, 10,
30, and 50 mM genistein for an additional 24 h. Whole-cell lysates
were harvested, and cell extracts were subjected to Western blot
analysis for the detection of AR protein.
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pleiotropic effects of genistein on hormone signal-
ing pathways.
The presence of androgen is critical for prostate
cancer development. The AR is expressed in prostate
cancer cells at all stages of the disease, including
androgen-independentmetastatic disease [37]. One-
third of androgen-independent tumors show ampli-
fication and overexpression of the AR gene, suggest-
ing that a functional AR pathway favors cell growth
[6]. The most frequent AR mutation found in
prostate cancers is the T877Amutation, which alters
ligand binding specificity such that it can bind to
and be activated by androgens, estrogens, proges-
terone, and antiandrogens and contributes to
aggressive cell growth [7]. Prostate cancer cells con-
taining mutant receptors, therefore, may have a
survival advantage in an androgen–deficient envi-
ronment. In this study, we showed that genistein
could inhibit AR protein and mRNA expression in
LNCaP cells in the absence or presence of androgen.
Additionally, we showed that the androgen-respon-
sive gene PSA was transcriptionally downregulated
by genistein in the absence or presence of androgen.
Other researchers and we have shown that genistein
treatment decreases prostate cancer cell growth and
induces apoptosis in an androgen-independent
manner [14,15,26]. These results provide evidence
to support the role of genistein as a potential thera-
peutic agent against both androgen-dependent and
androgen-independent prostate tumors.
It is well accepted that both androgens and estro-
gens play a critical role in prostate carcinogenesis.
Prostate cancer can be induced in Noble rats by
combined treatment with testosterone and 17b-
estradiol [38,39]. Testosterone treatment alone pro-
duces prostate adenocarcinomas in the dorsal lobe
of the prostate in 20% of Noble rats, but when
estrogen is administered simultaneously, prostatic
tumors appear more rapidly. The highest incidence
of prostate adenocarcinomas has been obtained
with prolonged exposure to androgen followed by
estrogen, indicating that estrogen plays a critical
role in the genesis of prostatic cancers. The precise
mechanism by which estrogens promote prostate
carcinogenesis is not known. Nevertheless, studies
have shown that b-estradiol increases AR gene trans-
activation and increases phosphorylation of AR in
LNCaP cells [32]. Additionally, PSA was shown to
be upregulated by progesterone and estrogen treat-
ment in LNCaP cells [10].
In contrast, exposure to phytoestrogens, particu-
larly soy isoflavones, has been associated inversely
with prostate cancer risk and has chemopreventive
properties in experimental animal models. In our
study, we showed that b-estradiol increased PSA
promoter activity and protein expression. Addi-
tionally, we found that genistein had a biphasic
dose-dependent response to b-estradiol–mediated
PSA expression. Low concentrations of genistein
increased PSA expression, whereas high concentra-
tions were inhibitory. It is conceivable that high
levels of genistein may be necessary in vivo for a
therapeutic effect, although low concentrations
of genistein do not enhance prostate cancer cell
growth in vitro. Further studies are required to
elucidate the differential effects of genistein on
estrogen-mediated and androgen-mediated signal-
ing pathways.
There are several dietary and related compounds
that negatively regulate androgen induction of PSA
expression in LNCaP cells. Retinoic acid treatment
decreases cell proliferation and significantly inhibits
PSA expression at the mRNA and protein levels [40].
Treatment with a synthetic retinoid, fenretinide,
represses LNCaP cell proliferation while increasing
apoptosis and downregulating PSA protein expres-
sion, which is preceded by a reduction of AR protein
expression [41]. Biochanin A, a metabolite of geni-
stein, decreases testosterone-stimulated PSA protein
expression in LNCaP cells as a result of increased
intracellular glucuronidation of testosterone [42].
Another isoflavone, quercetin, has been shown to
reduce PSA protein and mRNA levels and lowers AR
protein expression [43]. The mechanisms by which
these compounds lower PSA and AR levels have not
yet been elucidated.
There have been several reports that have exam-
ined the interaction of genistein and steroid re-
ceptors. Genistein has been shown to bind directly
to the estrogen receptor (ER) and modulate its
function. It is important to note that prostate
cancer cells express ER-b more often than ER-a,
indicating the role of these receptors in prostate
cancer. Genistein also can inhibit the transactivat-
ing function of the glucocorticoid receptor, pos-
sibly owing to inhibition of ligand-induced release
of the glucocorticoid receptor from heat shock
protein 90 [44]. Reinikainen et al. [45] reported
that genistein can suppress androgen induction of
an androgen-responsive chloram-phenicol acetyl-
transferase reporter gene transfected in HeLa cells.
In contrast, genistein does not have an effect on
androgen-induced activation of wild-type AR in PC3
cells [46]. The inconsistency of these results may
be due to different cell types, culture conditions,
growth factors, functional status of the AR, and
presence of AR co-activators and co-repressors. Re-
cent studies have shown that phytoestrogens have
differential effects on the ability of ER-a and ER-b to
bind co-activator proteins, which result in agonis-
tic/antagonistic responses [47,48].
In our study, we have shown that genistein inhi-
bited androgen-mediated regulation of PSA, but the
effects of genistein were dramatically different in
the presence of b-estradiol. The mechanism by
which genistein modulates b-estradiol–induced
PSA expression is unknown, but we have shown
that these effects were not due to changes in AR
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protein levels. Although it has not been determined
whether ER-a and ER-b, the natural receptors for
estrogens, directly regulate PSA expression, they
have been identified in prostate cancer specimens
and cell lines [49,50]. We are currently investigating
whether genistein modulates ER-a and ER-b func-
tions in LNCaP cells and whether these receptors
play a role in the regulation of PSA gene expression.
Nevertheless, our data on LNCaP cells directly corro-
borate the findings reported in a breast cancer cell
line, BT474, which was growth stimulated by andro-
gen and produced PSA. On the other hand, growth
and PSA production were significantly inhibited by
genistein but not by another phytoestrogen, quer-
cetin [51], documenting specific effects of genistein
on PSA exactly similar to our results.
In conclusion, our study showed that genistein
inhibited androgen-dependent and androgen-
independent PSA transactivation, possibly through
decreased binding to the ARE and decreased AR
protein levels. In addition, low concentrations
of genistein enhanced b-estradiol–mediated PSA
regulation, and high concentrations inhibited b-
estradiol–mediated PSA expression. These results
indicate the complex role of phytoestrogens in
modulating hormone signaling pathways and em-
phasize the importance of understanding their
molecular mechanism of action.
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